Patel Chirag J*1, Satyanand Tyagi2, Patel Kanu J3, Patel Tushar4, Patel Harnish K5, Patel Priyanka H6 1Maharishi Arvind Institute of Pharmacy, Mansarovar, Jaipur, Rajasthan, India-302020. 2Founder, President & CEO, Tyagi Pharmacy Association, Chattarpur, New Delhi, India-110074. 3Sharda School of Pharmacy, Pethapur, Gandhinagar, Gujarat, India. 4Aditya Bangalore Institute for Pharmacy Education & Research, Bangalore, Karnataka, India. 5Editor-In-Chief, IJPRBS Journal, Gujarat, India. 6Director, Research Scholar Hub, Gujarat, India
Huntington’s disease (HD) is an inherited disease of the central nervous system that usually has its onset between 30 and 50 years of age. The disease occurs in all racial groups but is most common in people of northern European origin. Although no therapy is currently available to delay the onset of symptoms or prevent the progression of the disease, symptomatic treatment of patients with Huntington disease (HD) may improve the quality of life and prevent complications. As is the case with other neurological diseases, HD makes individuals more vulnerable to side effects from medications, particularly cognitive adverse effects. Symptomatic treatment for HD can be divided into drugs to treat the movement disorder and drugs to treat psychiatric or behavioral problems. Symptomatic treatment of Huntington’s disease involves use of Dopamine antagonists, presynaptic dopamine depleters, Antidepressants, Tranquillizers, Anxiolytic Benzodiazepines, Anticonvulsants and Antibiotics. Several medications including baclofen, idebenone and vitamin E have studied in clinical trials with limited samples.
Key words: Huntington’s disease, Chorea, Neurodegenerative, Brain